Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Short-term Investments (2017 - 2025)

Corcept Therapeutics' Short-term Investments history spans 9 years, with the latest figure at $251.7 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 1.57% year-over-year to $251.7 million; the TTM value through Dec 2025 reached $251.7 million, down 1.57%, while the annual FY2025 figure was $251.7 million, 1.57% down from the prior year.
  • Short-term Investments for Q4 2025 was $251.7 million at Corcept Therapeutics, down from $296.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $365.3 million in Q4 2022 and bottomed at $145.9 million in Q4 2021.
  • The 5-year median for Short-term Investments is $258.3 million (2024), against an average of $264.7 million.
  • The largest annual shift saw Short-term Investments plummeted 59.97% in 2021 before it skyrocketed 150.38% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $145.9 million in 2021, then soared by 150.38% to $365.3 million in 2022, then plummeted by 36.31% to $232.7 million in 2023, then increased by 9.88% to $255.7 million in 2024, then fell by 1.57% to $251.7 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Short-term Investments are $251.7 million (Q4 2025), $296.5 million (Q3 2025), and $239.5 million (Q2 2025).